Vemurafenib has also been shown to activate melanoma‐associated stromal fibroblasts, increasing ECM production and elevating integrin/FAK/Src signaling to promote vemurafenib resistance in nearby melanoma cells (Hirata et al, 2015). This evidence concerns the gene PTK2 and melanoma.